2 completed, 1 terminated. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow 5-hydroxymethylfurfural: new trials by email Literature Review of 5-hydroxymethylfurfural trials Research Report on 5-hydroxymethylfurfural
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Different Dose Regimens of Aes-103 Given for 28 Days to Subjects With Stable Sickle Cell Disease Aes-103, Placebo - Sickle Cell Disease | Phase 2 | Terminated | Baxalta now part of Shire | 35 | 2013-12-03 | 2021-05-25 |
| Evaluation of the Attenuation by Aes-103 of Hypoxia Mediated Decrements in Endurance Exercise Performance Placebo, Aes-103 - Hypoxia | Phase 1 / Phase 2 | Completed | Colorado State University | 12 | 2013-03-01 | 2014-10-24 |
| A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease Aes-103, Placebo - Sickle Cell Disease | Phase 1 | Completed | Baxalta now part of Shire | 19 | 2012-05-12 | 2021-05-05 |
Anemia, Sickle Cell (2) · Anemia (1) · Hypoxia (1) · Motor Activity (1) · Pain (1)
Baxalta now part of Shire (2) · Colorado State University (1)
United States (2) · United Kingdom (1)
1ZIAHL006149-01 (1)